Developmental Delay and School Performance Among Retinoblastoma Survivors: Development/school Morbidity Among Retinoblastoma Survivors

Overview

Journal Am J Ophthalmol

Specialty Ophthalmology

Date 2021 May 9

PMID 33965417

Citations 1

Authors

Margaret Reynolds

Gregg Lueder

Mae Gordon

Robert J Hayashi

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to describe the academic performance of childhood retinoblastoma (RB) survivors.

Design: Retrospective cohort study.

Methods: Retrospective chart review of children followed in a survivorship clinic.

Results: A total of 73 patients with RB (median age at diagnosis: 9.97 months; range: 0.29-65.1) were followed for a median of 6.4 years (0.2-1.76). A total of 48 patients (65.8%) had unilateral RB; 43 patients (63.0%) received systemic chemotherapy; and 57 patients (78.1%) underwent enucleation. At last follow-up, 5 children (6.8%) had bilateral visual acuity (VA) <20/70. Seventeen subjects (23.3%) reported school difficulties, and 10 subjects (13.7%) had an individualized education program (IEP). Multivariate analysis revealed that a history of receiving chemotherapy" Multivariate analysis revealed that a history of receiving chemotherapy was associated with self-reported school difficulties (odds ratio [CI]: 5.44; 95% confidence interval [CI]: 1.36-21.69; P = .016), and undergoing an IEP (OR: 11.47; 95% CI: 1.34-98.16; P = .03). The degree of visual impairment and history of enucleation did not influence the risk of self-reported school difficulties or the implementation of an IEP. Among unilateral RB patients, chemotherapy was an independent risk factor for self-reported school difficulties (OR: 12.8; 95% CI: 1.45-113; P = .009) and implementation of an IEP (OR: 15.2; 95% CI: 0.78-292; P = .02).

Conclusions: Academic difficulties in childhood RB survivors are associated with chemotherapy treatment, a risk factor independent of VA.

Citing Articles

Reading level, acuity, and speed evaluation among retinoblastoma survivors: A prospective case series.

Barnett S, Malone S, Strelnikov J, LHotta A, Zabotka L, Lueder G Rare Tumors. 2024; 16:20363613241306191.

PMID: 39665086 PMC: 11632865. DOI: 10.1177/20363613241306191.

References

Bathelt J, de Haan M, Dale N . Adaptive behaviour and quality of life in school-age children with congenital visual disorders and different levels of visual impairment. Res Dev Disabil. 2018; 85:154-162. DOI: 10.1016/j.ridd.2018.12.003. View

Bornstein M, Scrimin S, Putnick D, Capello F, Haynes O, de Falco S . Neurodevelopmental functioning in very young children undergoing treatment for non-CNS cancers. J Pediatr Psychol. 2012; 37(6):660-73. PMC: 3381709. DOI: 10.1093/jpepsy/jss003. View

Mohrmann C, Henry J, Hauff M, Hayashi R . Neurocognitive outcomes and school performance in solid tumor cancer survivors lacking therapy to the central nervous system. J Pers Med. 2015; 5(2):83-90. PMC: 4493487. DOI: 10.3390/jpm5020083. View

Narang S, Mashayekhi A, Rudich D, Shields C . Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Exp Ophthalmol. 2012; 40(7):736-42. DOI: 10.1111/j.1442-9071.2012.02757.x. View

Askins M, Moore 3rd B . Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol. 2008; 23(10):1160-71. PMC: 3674758. DOI: 10.1177/0883073808321065. View

Mitby P, Robison L, Whitton J, Zevon M, Gibbs I, Tersak J . Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2003; 97(4):1115-26. DOI: 10.1002/cncr.11117. View

Friedman D, Himelstein B, Shields C, Shields J, Needle M, Miller D . Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000; 18(1):12-7. DOI: 10.1200/JCO.2000.18.1.12. View

Dimaras H, Kimani K, Dimba E, Gronsdahl P, White A, Chan H . Retinoblastoma. Lancet. 2012; 379(9824):1436-46. DOI: 10.1016/S0140-6736(11)61137-9. View

Chantada G, Qaddoumi I, Canturk S, Khetan V, Ma Z, Kimani K . Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer. 2011; 56(3):341-8. DOI: 10.1002/pbc.22843. View

10.

Daw N . Critical periods and amblyopia. Arch Ophthalmol. 1998; 116(4):502-5. DOI: 10.1001/archopht.116.4.502. View

11.

Hall L, Ceisler E, Abramson D . Visual outcomes in children with bilateral retinoblastoma. J AAPOS. 1999; 3(3):138-42. DOI: 10.1016/s1091-8531(99)70058-3. View

12.

Dosman C, Andrews D, Goulden K . Evidence-based milestone ages as a framework for developmental surveillance. Paediatr Child Health. 2013; 17(10):561-8. PMC: 3549694. DOI: 10.1093/pch/17.10.561. View

13.

Kadan-Lottick N, Zeltzer L, Liu Q, Yasui Y, Ellenberg L, Gioia G . Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst. 2010; 102(12):881-93. PMC: 2886093. DOI: 10.1093/jnci/djq156. View

14.

Grandinette S . Supporting students with brain tumors in obtaining school intervention services: the clinician's role from an educator's perspective. J Pediatr Rehabil Med. 2014; 7(4):307-21. DOI: 10.3233/PRM-140301. View